EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieOpen Access · CC BY 4.0

Remission outcomes with bupropion versus selective serotonin reuptake inhibitors in major depressive disorder with comorbid obesity: A propensity-matched cohort analysis

Farah Khorassani, Justin Schneider, Jonathan Prunean, Gemma Espejo

Journal of Affective Disorders · 2026-12 · 414 · 122398

DOI: 10.1016/j.jad.2026.122398 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Affective Disorders, 2026-12. Verfasst von Farah Khorassani und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of California, Irvine School of Pharmacy and Pharmaceutical Sciences, Department of Clinical Pharmacy Practice, 802 Berk Hall, Irvine, Cal…. Hauptthemen laut MEDLINE: Bupropion, Major Depressive Disorder, Selective Serotonin Reuptake Inhibitors, Obesity. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Observational and secondary analyses of clinical trials evaluating efficacy of antidepressants suggest that medications with noradrenergic and dopaminergic mechanisms of action may be more effective in managing symptoms of major depressive disorder (MDD) in obese patients than medications that are purely serotonergic. The purpose of this study is to compare the efficacy of bupropion versus SSRIs in patients without a documented antidepressant trial with comorbid MDD and obesity. This was a retrospective, propensity-score matched, observational study utilizing a global cohort within the TriNetX database. Adults aged 18 or over with a major depressive episode and obesity were grouped into two cohorts: 1) exposure to bupropion and 2) exposure to SSRIs. Patients with antidepressant exposure prior to the index event were excluded. Both cohorts were propensity matched based on 16 covariates. The primary outcome was remission of a major depressive episode. Secondary outcomes included evaluating socioeconomic and psychosocial differences between the groups. Each cohort yielded 165,629 patients. The primary endpoint analysis indicated a small but statistically significant difference in MDD remission rates in favor of bupropion with an absolute risk rate of 8.5% compared to 7.9% in the SSRI group (Risk Ratio [RR] 1.07, 95% CI 1.05-1.10, p < 0.0001). Binary outcomes were summarized using risk differences and risk ratios and compared between cohorts using chi-square tests. Our findings suggest bupropion monotherapy was associated with a small but statistically significant higher remission rate compared with SSRIs but further prospective studies using objective remission indicators are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BupropionMajor Depressive DisorderSelective Serotonin Reuptake InhibitorsObesityAntidepressive Agents, Second-GenerationHumansPropensity ScoreAdultFemaleMaleRetrospective StudiesMiddle AgedRemission InductionTreatment OutcomeComorbidityCohort Studies

Stichwörter der Autor:innen

BupropionMajor depressive disorderObesityReal-world evidenceRemissionSSRIs

Substanzen

BupropionSelective Serotonin Reuptake InhibitorsAntidepressive Agents, Second-Generation

Autor:innen und Institutionen

  • University of California, Irvine School of Pharmacy and Pharmaceutical Sciences, Department of Clinical Pharmacy Practice, 802 Berk Hall, Irvine, California, 92697, United States of America. Electronic address: fkhorass…
  • University of California, Irvine School of Medicine, Department of Surgery, 836 Health Sciences Road, Irvine, CA, 92697, United States of America.
  • University of California, Irvine Alpha Clinic, 101 The City Drive South, Bldg 25C, Room 220, Orange, CA, 92868, United States of America.
  • University of California, Irvine School of Medicine, Department of Psychiatry and Human Behavior, 3800 West Chapman Avenue, Orange, CA, 92868, United States of America.

Zitieren

APA

Khorassani, F., Schneider, J., Prunean, J., & Espejo, G. (2026). Remission outcomes with bupropion versus selective serotonin reuptake inhibitors in major depressive disorder with comorbid obesity: A propensity-matched cohort analysis. Journal of Affective Disorders, 414, 122398. https://doi.org/10.1016/j.jad.2026.122398

Vancouver

Khorassani F, Schneider J, Prunean J, Espejo G. Remission outcomes with bupropion versus selective serotonin reuptake inhibitors in major depressive disorder with comorbid obesity: A propensity-matched cohort analysis. Journal of Affective Disorders. 2026;414:122398. doi:10.1016/j.jad.2026.122398

BibTeX
@article{Khorassani2026,
  author = {Khorassani, Farah and Schneider, Justin and Prunean, Jonathan and Espejo, Gemma},
  title = {Remission outcomes with bupropion versus selective serotonin reuptake inhibitors in major depressive disorder with comorbid obesity: A propensity-matched cohort analysis},
  journal = {Journal of Affective Disorders},
  year = {2026},
  volume = {414},
  pages = {122398},
  doi = {10.1016/j.jad.2026.122398}
}
Kostenlos starten →